Actively Recruiting
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-08-01
90
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC
CONDITIONS
Official Title
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign informed consent
- Age 18 years or older, any gender
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed treatment-na�efve Stage II-IIIB (N2 only) NSCLC as per AJCC 8th edition
- Only T4 tumors based on size allowed; other T4 conditions excluded
- Primary NSCLC must be considered resectable by a multidisciplinary team including a thoracic oncologic surgeon
- Ability to provide recent tumor tissue samples suitable for biomarker analysis
- At least one measurable lesion by RECIST v1.1 criteria
You will not qualify if you...
- Presence of confirmed EGFR or ALK positive mutations
- History of other cancers within past 5 years or concurrent malignancies, except certain treated skin, cervical, or prostate cancers
- Previous treatment with immune checkpoint inhibitors, T-cell receptor targeting drugs, immune checkpoint agonists, or immune cell therapy
- History of allogeneic hematopoietic stem cell or solid organ transplant, except corneal transplant
- Presence of congenital or acquired immunodeficiency, such as HIV infection
- History of severe allergic reactions to monoclonal antibodies
- Any other conditions or factors that might affect study outcomes or safety, including substance abuse, serious diseases, significant lab abnormalities, or social/family issues
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
Beijing, China
Actively Recruiting
Research Team
S
Shugeng Gao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here